AD Pipeline Update: Nektar’s Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Phase 2b Study
Nektar Therapeutics’ rezpegaldesleukin achieved primary and key secondary efficacy endpoints in the 16-week induction period of the ongoing Phase 2b of patients with moderate-to-severe atopic dermatitis (AD).